黄连素联合维生素E烟酸酯治疗冠心病合并血脂异常78例的观察

Observation of the berberine therapy combined vitamin E nicotinate in 78 patients with coronary artery disease complicated dyslipidemia

目的:研究黄连素联合维生素E烟酸酯治疗冠心病合并血脂异常的疗效、安全性和经济性。方法:比较78例冠心病合并血脂异常患者口服黄连素0.5g,2次/d,+维生素E烟酸酯0.1g,2次/d(治疗组),与辛伐他汀20mg,1次/d,治疗72例冠心病合并血脂异常患者(辛伐他汀对照组)的疗效。结果:治疗组的甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C)达标率和改变幅度均显著优于辛伐他汀(P<0.05,P<0.01);对总胆固醇的降低与辛伐他汀组没有显著性差异(P>0.05);并且治疗组的副作用和患者依从性显著优于辛伐他汀,每天患者的费用亦显著低于辛伐他汀(0.85元∶7.5元)。结论:黄连素联合维生素E烟酸酯是对冠心病合并血脂异常者一种有效、安全和经济的治疗组合,值得推广。

Objective： To study the efficacy, safety and economy of the berberine therapy combined vitamin E nicotinate in patients with coronary artery disease （CAD） complicated dyslipidemia. Methods.. The 78 CAD patients with dyslipidemia （therapy group） had been orally administrated berberine 0. 5g 2 times/d, ＋ vitamin E nicotinate 0. 1g 2 times/d for 2 months, and other 72 cases had orally administrated simvastatin 20 mg one time/d for 2 months （simvastatin group）. Results： The control rates and improved amplitudes of the TG, LDL-C and HDL-C in therapy group were significantly more than those of simvastatin group （P〈0.05, d0. 01） ; but there was no significant difference of TC between therapy group and simvastatin group （P〈0. 05） ; the cost of therapy group was significant lower than that of simvastatin group. Conclusion： The berberine therapy combined vitamin E nicotinate is an effective, safe and economic therapy to coronary artery disease complicated dyslipidemia.